ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 781

Rho Kinase (ROCK) Activity in Aortitis: Comparison of Giant Cell Arteritis (GCA), Takayasu Arteritis (TA) and Isolated Aortitis (IA)

Lindsay Lally1, Navneet Narula2 and Robert F. Spiera1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Pathology, Weill Cornell Medical College, New York, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Takayasu.s arteritis and giant cell arteritis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

 

Background/Purpose Aberrant ROCK activity is implicated in the pathogenesis of many autoimmune and vascular disease states as ROCKs promote Th17 differentiation and vascular remodeling.  Increased ROCK activity has been demonstrated in temporal artery biopsies from GCA patients and ROCK is proposed to play a role in aortic aneurysm formation; however the role of ROCK in aortitis is unknown.  The aim of this study was to assess ROCK activity in aortic specimens from patients with GCA, TA and IA.

 

Methods All aortic aneurysm specimens with histopathologic evidence of aortitis diagnosed during a 1 year period at a single institution identified and corresponding medical record reviewed.  Patient history and ACR criteria were used to confirm diagnosis of GCA, TA, or IA.  Those with IgG4 disease were excluded.  Paraffin-embedded specimens were stained for Phospho-Ezrin/Radixin/Moesin (pERM), a surrogate of ROCK activity, using immunohistochemical stain.  Sections also stained for the un-phosphorylated ERM protein.  Inflammatory cells characterized using CD3/CD20 stain for T/B cells.  Aortic specimens without aortitis were also stained for ERM/pERM as controls. Stained slides reviewed by a pathologist blinded to clinical status. pERM intensity in the vasculature and inflammatory infiltrate was assessed. 

 

Results Of 12 eligible aortitis cases, 4 were in those with prior history of GCA, 3 had TA and 5 had IA. Expected demographic differences noted between groups.

In all compartments, pERM staining was notably more intense than ERM suggesting activation of ROCK.  All patients with aortitis had >50% of the inflammatory infiltrate staining positive for pERM, though TA patients had greater proportion of pERM negative inflammatory cells (CD 163+ histiocytes) than those with GCA or IA.  All patients, including 10 with non-inflammatory aortic aneurysms, had intense pERM staining of stromal cells in the adventitia and vasa vasorum, which was not affected by use of medications or co-morbidities known to influence ROCK (Table 1).   

 

Conclusion  The markedly more intense pERM staining compared to ERM in the vasculature and lymphocytic infiltrate from those with GCA, TA, and IA suggest the ROCK pathway is active in these disease states, though no major differences in stain intensity between groups was noted.  The pERM intensity in vessels of non-aortitis aneurysm controls supports the idea that ROCK may promote aneurysm development.  ROCK activation likely reflects a response to vascular damage and repair regardless of etiologic mechanism, though staining in the infiltrating lymphocytes suggests ROCK is also involved in the inflammatory response in aortitis.  These findings may ultimately have therapeutic implications, if confirmed in larger cohorts, especially in GCA as inhibition of ROCK may mitigate the initial inflammatory milieu as well as aneurysm formation, the most significant late disease manifestation.  

 

 

 

 

Table 1: Patient Demographics

Subject

Age (yr)/Sex

Diagnosis/Disease Duration (yr)

Immunosuppression

Symptoms*

Statin Use

ACE-Inhibitor Use

Tobacco Use

Hypertension

1

79/M

GCA/8

Prednisone 10mg

PMR

n

y

former

y

2

71/M

GCA/4

NA

n

y

former

y

3

78/F

IA

NA

y

y

former

y

4

73/M

IA

NA

n

n

former

y

5

60/M

IA

NA

n

y

n

y

6

76/M

GCA/8

NA

vision loss

y

y

n

y

7

64/F

IA

Prednisone 3mg**

n

n

former

n

8

71/M

GCA/5

Prednisone 2mg

HA/PMR

y

n

former

y

9

32/F

TAK

NA

n

n

n

n

10

28/F

TAK/1

Prednisone 40mg

fever/weight loss

n

n

n

n

11

40/F

TAK/1

Remicade 5mg/kg

arthritis, limb claudication

n

n

n

y

12

42/M

IA

NA

n

n

former

y

GCA= Giant Cell Arteritis  TAK=Takaysu Arteritis IA=Isolated Aortitis  PMR=Polymyalgia Rheumatica HA=headache

n=no y=yes

*Symptoms at time of presentation

**Steroids for congenital adrenal hyperplasia

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Disclosure:

L. Lally,
None;

N. Narula,
None;

R. F. Spiera,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rho-kinase-rock-activity-in-aortitis-comparison-of-giant-cell-arteritis-gca-takayasu-arteritis-ta-and-isolated-aortitis-ia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology